Compare PROV & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PROV | ACOG |
|---|---|---|
| Founded | 1956 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0M | 110.4M |
| IPO Year | 2009 | N/A |
| Metric | PROV | ACOG |
|---|---|---|
| Price | $17.08 | $7.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $16.25 | $16.00 |
| AVG Volume (30 Days) | 6.1K | ★ 31.1K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.14 | $139.22 |
| Revenue Next Year | $3.70 | $134.48 |
| P/E Ratio | $25.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.95 | $4.50 |
| 52 Week High | $17.42 | $10.88 |
| Indicator | PROV | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 69.57 |
| Support Level | $16.91 | $6.46 |
| Resistance Level | $17.38 | $7.69 |
| Average True Range (ATR) | 0.28 | 0.36 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 78.26 | 99.50 |
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.